Comparison of single-agent chemotherapy and targeted therapy to first-line treatment in patients aged 80 years and older with advanced non-small-cell lung cancer
Zhehai Wang(Shandong Tumor Hospital), Yang Liu(Sun Yat-sen University), Qianqian Zhang(Anhui Medical University), Xiao Han(Shandong Tumor Hospital), Liyan Liu(Shandong Tumor Hospital), Minmin Li(First Affiliated Hospital of Jinan University), Ning Tang(Hebei Medical University), Jun Guo(Shandong Tumor Hospital), Shu Fang(Peking University), Xiang Bi(Shandong First Medical University)
Cited by 23
Related Papers
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adaptive genic evolution in the <i>Drosophila</i> genomes
|Proceedings of the National Academy of Sciences|2007|227
Multifunctional TiO2/C nanosheets derived from 3D metal–organic frameworks for mild-temperature-photothermal-sonodynamic-chemodynamic therapy under photoacoustic image guidance
|Journal of Colloid and Interface Science|2022|222